Israeli investigators intend to evaluate the potential anti-tumoral effects of the canabinoid cannabidiol (CBD) in select cancer patients.
Researchers at the Hassadah Medical Center in Jerusalem will conduct a Phase II clinical trial to assess the impact of CBD as single treatment in cancer patients who have failed to respond to conventional therapies. Participants in the trial will receive CBD therapy for a period of eight weeks.
Data documenting the potent anti-cancer activity of various cannabinoids – including THC, CBD, and CBG – both in culture and in animals dates back to the mid-1970s. To date, however, virtually no clinical trials exist reproducing these results in human subjects.
In August, pharmaceutical provider Insys Therapeutics announced that it had received orphan drug status for its proprietary formulation of CBD for the treatment of glioblastoma, a hard-to-treat, aggressive form of brain cancer.
Organic CBD remains classified under federal law as a schedule I controlled substance.
Further details of the forthcoming Israeli trial are available online from the clinicaltrials.gov website here. Patient recruitment has yet to begin for this study.
Traumatic brain injury (TBI) patients with a history of cannabis use possess increased survival rates compared to non-users, according data published this month in the scientific journal The American Surgeon.
UCLA Medical Center investigators conducted a three-year retrospective review of brain trauma patients. Data from 446 separate cases of similarly injured patients was assessed. Of those patients who tested positive for the presence of marijuana, 97.6 percent survived surgery. By contrast, patients who tested negative for the presence of pot prior to surgery possessed only an 88.5 percent survival rate.
“[O]ur data suggest an important link between the presence of a positive THC screen and improved survival after TBI,” the authors concluded. “This finding has support in previous literature because the neuroprotective effects of cannabinoids have been implicated in a variety of neurodegenerative diseases such as Alzheimer’s disease, Huntington’s disease, and multiple sclerosis. … With continued research, more information will be uncovered regarding the therapeutic potential of THC, and further therapeutic interventions may be established.”
The abstract of the study, “Effect of marijuana use on outcomes in traumatic brain injury,” appears online here.
Study: CBD Administration Associated With Improved Quality Of Life In Patients With Parkinson’s DiseaseSeptember 25, 2014
The administration of cannabidiol (CBD), a nonpsychotropic cannabinoid, is associated with improved quality of life in patients with Parkinson’s disease, according clinical trial data published online ahead of print in the Journal of Psychopharmacology.
Investigators at the University of São Paulo in Brazil assessed the efficacy of CBD versus placebo in 21 subjects with Parkinson’s. Authors reported that the administration of 300 mg doses of CBD per day was associated with “significantly different mean total scores” in subjects’ well-being and quality of life compared to placebo.
Separate assessments of CBD versus placebo reported that the cannabinoid did not appear to mitigate general symptoms of the disease, nor was it shown to be neuroprotective.
“This study points to a possible effect of CBD in improving measures related to the quality of life of PD patients without psychiatric comorbidities,” investigators concluded. They added, “We found no statistically significant differences concerning the motor symptoms of PD; however, studies involving larger samples and with systematic assessment of specific symptoms of PD are necessary in order to provide stronger conclusions regarding the action of CBD in PD.”
Clinical reports have previously indicated that both CBD and/or whole-plant cannabis may address various symptom’s of Parkinson’s disease, including improvement in motor symptoms, pain reduction, improved sleep, and a reduction in the severity of psychotic episodes.
Survey data of patients with PD indicates that almost half of all subjects who try cannabis report experiencing subjective relief from the plant.
The abstract of the study, “Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial,” appears online here.
Marijuana use by newly married couples is predictive of less frequent incidences of intimate partner violence perpetration, according to longitudinal data published online ahead of print in the journal Psychology of Addictive Behaviors.
Investigators at Yale University, Rutgers, and the University of Buffalo assessed over 600 couples to determine whether husbands’ and wives’ cannabis use was predictive of domestic abuse at any time during the first nine years of marriage. Researchers reported: “In this community sample of newly married couples, more frequent marijuana use generally predicted less frequent IPV perpetration, for both men and women, over the first 9 years of marriage. Moderation analyses provided evidence that couples in which both spouses used marijuana frequently were at the lowest risk for IPV perpetration, regardless of the perpetrator’s gender.”
Stated the study’s lead author in a press release: “Although this study supports the perspective that marijuana does not increase, and may decrease, aggressive conflict, we would like to see research replicating these findings, and research examining day-to-day marijuana and alcohol use and the likelihood to IPV on the same day before drawing stronger conclusions.”
According to a previous study, published in January in the journal Addictive Behaviors, alcohol consumption — but not cannabis use — is typically associated with increased odds of intimate partner violence. Authors reported: “On any alcohol use days, heavy alcohol use days (five or more standard drinks), and as the number of drinks increased on a given day, the odds of physical and sexual aggression perpetration increased. The odds of psychological aggression increased on heavy alcohol use days only.” By contrast, researchers concluded that “marijuana use days did not increase the odds of any type of aggression.”
The abstract of the study, “Couples’ marijuana use is inversely related to their intimate partner violence over the first 9 years of marriage,” is online here.
The enactment of medicinal marijuana laws is associated with significantly lower state-level opioid overdose mortality rates, according to data published online today in the Journal of the American Medical Association (JAMA) Internal Medicine.
A team of investigators from the University of Pennsylvania, the Albert Einstein College of Medicine in New York City, and the Johns Hopkins Bloomberg School of Public Health in Baltimore conducted a time-series analysis of medical cannabis laws and state-level death certificate data in the United States from 1999 to 2010 — a period during which 13 states instituted laws allowing for cannabis therapy.
Researchers reported, “States with medical cannabis laws had a 24.8% lower mean annual opioid overdose mortality rate compared with states without medical cannabis laws.” Specifically, overdose deaths from opioids decreased by an average of 20 percent one year after the law’s implementation, 25 percent by two years, and up to 33 percent by years five and six.
They concluded, “In an analysis of death certificate data from 1999 to 2010, we found that states with medical cannabis laws had lower mean opioid analgesic overdose mortality rates compared with states without such laws. This finding persisted when excluding intentional overdose deaths (ie, suicide), suggesting that medical cannabis laws are associated with lower opioid analgesic overdose mortality among individuals using opioid analgesics for medical indications. Similarly, the association between medical cannabis laws and lower opioid analgesic overdose mortality rates persisted when including all deaths related to heroin, even if no opioid analgesic was present, indicating that lower rates of opioid analgesic overdose mortality were not offset by higher rates of heroin overdose mortality. Although the exact mechanism is unclear, our results suggest a link between medical cannabis laws and lower opioid analgesic overdose mortality.”
In a written statement to Reuters Health, lead author Dr. Marcus Bachhuber said: “Most of the discussion on medical marijuana has been about its effect on individuals in terms of reducing pain or other symptoms. The unique contribution of our study is the finding that medical marijuana laws and policies may have a broader impact on public health.”
Added co-author Colleen L. Barry in USA Today: “[The study’s findings] suggest the potential for many lives to be saved. … We can speculate … that people are completely switching or perhaps supplementing, which allows them to lower the dosage of their prescription opioid.”
Nationwide, overdose deaths involving opioid analgesics have increased dramatically over the past decade. While fewer than 4,100 opiate-induced fatalities were reported for the year 1999, by 2010 this figure rose to over 16,600 according to an analysis by the US Centers for Disease Control.
An abstract of the JAMA study, “Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999-2010,” appears online here.